You can receive independent, expert advice on alcohol rehabilitation and rehab centres by telephoning DryOutNow.com on 0845 370 0203

The most important consideration in choosing a rehab centre is to match the individual to the rehab centre that is most likely to lead to a successful outcome.

DryOutNow.com can provide an assessment of all your needs and a recommendation regarding the most effective rehab placement for you, given your particular circumstances. We can provide fast, immediate access to alcohol treatment.

Two recent studies give hope to individuals who experience the physical, mental and social symptoms associated with alcohol dependence.

Researchers at the Medical University of South Carolina (MUSC) found favourable results for a medication to help heavy drinkers who are trying to modify their consumption, as well as a medication to reduce alcohol withdrawal symptoms and prevent relapse.

In a landmark study, MUSC researchers working with investigators at the University of Virginia Health System and elsewhere have found that topiramate, an effective therapeutic medication, not only decreases heavy drinking, but it also lowers all liver enzymes, plasma cholesterol, body mass index (BMI), and systolic and diastolic blood pressure — all of which tend to increase with heavy drinking and pose such serious health risks as heart disease and cirrhosis.
Notably, these combined effects suggest that topiramate may decrease the risk of heart disease in alcohol dependent individuals.

"These findings add growing data indicating that heavy drinkers who modify their drinking with the help of medication and supportive counselling may see an improvement in health and well-being, as well as a potential reduction of risk for the development of heart and liver diseases. This shows that treatment of alcoholism has potential health benefits beyond the immediate behavioural and emotional improvement caused by a reduction in drinking" said Raymond Anton, M.D.

By decreasing liver enzymes and cholesterol levels, topiramate also may reduce the risk of fatty liver disease, which leads to cirrhosis - a common consequence to end-stage liver disease leading to death in some alcoholics.

Additionally, topiramate significantly contributed to a decline in obsessive thoughts and compulsions, components of alcohol craving, and participants also had a greater improvement in their "overall quality of life," and specifically an improvement in general and leisure activities and household duties, as well as a reduction in sleep disturbances.
The Food and Drug Administration has approved topiramate for seizures and migraine headaches, but it is not currently approved for treating alcohol dependence. Ortho-McNeil Neurologics, Inc., manufactures topiramate and provided study funding.

Results from the nationwide 14-week trial, involving 371 male and female diagnosed alcoholics, were published in the June 9 issue of the Archives of Internal Medicine.

In addition, Anton presented initial results from a separate investigation of a 14-week double-blind, placebo-controlled study utilizing the PROMETA ® alcoholism treatment programme, developed by Hythiam, inc., at the 2008 Research Society on Alcoholism (RSA) conference in Washington D.C.

Anton suggested that alcohol dependence programs are few in number and not exceptionally effective, which is particularly true for individuals who experience alcohol withdrawal symptoms. PROMETA ®, a combination of generic medications, reduced cravings and alcohol withdrawal symptoms, promoted abstinence, and improved mood and sleep only in those who had symptoms of alcohol withdrawal.

Although the PROMETA ® Protocol has been marketed nationally, this was the first scientific study examining its utility in individuals with alcohol dependence.

At the time of the RSA presentation, the data presented covered the initial six-week active treatment phase of the 14-week study. While these are initial findings, additional evaluation of the full 14-week study data is ongoing, and Anton plans to release these specifics in a peer-reviewed publication.

Bankole A. Johnson et al, ‘Improvement of Physical Health and Quality of Life of Alcohol-Dependent Individuals With TopiramateTrea tment: US Multisite Randomized Controlled Trial', Arch Intern Med. 2008;168(11):1188-1199.

Article published on 31/07/2008 by DryOutNow.com

DryOutNow.com provides highly practical help for people with alcohol problems, their friends and relatives. DryOutNow.com also provides free resources for healthcare professionals such as medical information and alcohol treatment guidelines.

• New medication could offer hope for alcohol addiction ...... read
• Risky drinking in over-55s becomes the focus of new research ...... read
• Counselling during drug addiction treatment reduces unsafe sexual behaviour ...... read
• Coffee and cigarette consumption high among AA attendees ...... read
• NIDA explores exercise as drug abuse prevention tool ...... read
• Conference to look at reversing and preventing alcohol-induced dementia ...... read
• The treatment of alcoholism: How recent research impacts on clinicians ...... read
• Does gene variant make women more prone to alcoholism? ...... read
• US State policies influence drug treatment programmes ...... read
• Binge drinking findings have implications for policy makers ...... read
• Review of underage drinking prevention programmes published ...... read
• Scientifically valid prevention programmes cut rates of juvenile delinquency ...... read
• United Nations Drugs Day ...... read
• Survey of Hispanics and alcohol dependence to be expanded ...... read
• Exposure-based addiction therapies could be extremely effective ...... read
• NTA chief calls for balanced drug treatment ...... read
• Breakthrough in Alcohol Addiction Treatment ...... read
• Alcoholics Anonymous and Narcotics Anonymous benefit adolescents who attend ...... read
• Treatment centres urged to open doors during Misuse and Addictions Week ...... read
• Support available for Scottish drug recovery programme ...... read